Research - Hamburg, Hamburg, Germany
provecs is pioneering next-generation tumor gene therapy to expose the tumor to the immune system. The Company´s proprietary enviro adenoviral platform enables the targeted delivery of up to four biologicals combined in one product, thereby activating both the innate and the adaptive immune system.provecs also has established a comprehensive proof-of-concept platform named exviro® for ex-vivo therapy simulation in primary human cancer tissues. exviro®allows the monitoring of immune processes by big data transcriptome profiling, bioinformatics, and tissue immune imaging technologies.
Apache